Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Innovative Industrial Properties Inc (IIPR) vs 10X Genomics Inc (TXG) Price & Performance

Innovative Industrial Properties IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Innovative Industrial Properties Inc vs 10X Genomics Inc — how do they compare? Innovative Industrial Properties Inc trades at $58.5 (market cap $1.67B), while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 4.6× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays a 13.18% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

IIPRTXG
Market Cap
$1.67B$7.61B
Sector
Real EstateHealth
52-Week High
$64.67$58.57
52-Week Low
$44.58$11.34
Enterprise Value
$2.21B$7.14B
Dividend Yield
13.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Innovative Industrial Properties Inc

IIPR trades at $57.69, showing modest daily gains of 0.37%. The stock presents mixed signals with bearish technical indicators but strong fundamentals including a P/E of 13.05 and net margin of 52.27%. Recent Q2 2026 earnings beat expectations with $1.36 EPS versus $1.02 forecast. The company maintains robust cash flow from operations at $198.19M and recently declared a $1.90 dividend for H1-2026.

Outlook remains cautiously optimistic despite technical weakness. The 9.09% dividend yield and attractive valuation metrics provide support, but declining revenue from $266M (2025) to $264M (2026) and tenant concentration risks in the cannabis REIT sector warrant monitoring. Analyst consensus leans Hold (54.55%) with institutional interest growing.

10X Genomics Inc

TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.

Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.

Returns comparison

Trailing returns across standard periods

About Innovative Industrial Properties Inc

Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.

Read more on IIPR

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG